Subtle variations in Pten dose determine cancer susceptibility

Nature Genetics

Volumn 42, Issue 5, 2010, Pages 454-458

  Alimonti, Andrea ^a,b,c,d   Carracedo, Arkaitz ^a,b,c,d   Clohessy, John G ^a,b,c,d   Trotman, Lloyd C ^c,g   Nardella, Caterina ^a,b,c,d   Egia, Ainara ^a,b,c,d   Salmena, Leonardo ^a,b,c,d   Sampieri, Katia ^a,b   Haveman, William J ^a,b,c,d   Brogi, Edi ^d   Richardson, Andrea L ^e   Zhang, Jiangwen ^f   Pandolfi, Pier Paolo ^a,b,c,d  

^a Cancer Genetics Program   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c Cancer Biology and Genetics Program   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f HARVARD UNIVERSITY   (United States)

^g Howard Hughes Medical Institute Cold Spring Harbor Laboratory Cold Spring Harbor   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; GENE DOSAGE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE MUTATION; HETEROZYGOSITY; HUMAN; INTESTINE POLYP; LUNG CANCER; LYMPHADENOPATHY; MOUSE; NONHUMAN; PENETRANCE; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; PTEN GENE; TUMOR SUPPRESSOR GENE; UTERUS CANCER;

ANIMALS; BREAST NEOPLASMS; FEMALE; GENE DOSAGE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; MALE; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, TRANSGENIC; MODELS, GENETIC; MUTATION; PTEN PHOSPHOHYDROLASE;

MUS;

EID: 77951765345     PISSN: 10614036     EISSN: 15461718     Source Type: Journal    
DOI: 10.1038/ng.556     Document Type: Article

References (21)

1. Friend, S.H. Alfred Knudson: the importance of a visionary who enables scientists. Genes Chromosom. Cancer 38, 326-328 (2003). (Pubitemid 37466932)
2. Trotman, L.C. et al. Pten dose dictates cancer progression in the prostate. PLoS Biol. 1, E59 (2003).
3. Yan, H. et al. Small changes in expression affect predisposition to tumorigenesis. Nat. Genet. 30, 25-26 (2002).
4. Salmena, L., Carracedo, A. & Pandolf, P. P. Tenets of PTEN tumor suppression. Cell 133, 403-414 (2008). (Pubitemid 351622014)
5. Knudson, A.G. Two genetic hits (more or less) to cancer. Nat. Rev. Cancer 1, 157-162 (2001).
6. Knudson, A.G. Hereditary cancer: two hits revisited. J. Cancer Res. Clin. Oncol. 122, 135-140 (1996).
7. Ma, L. et al. Genetic analysis of Pten and Tsc2 functional interactions in the mouse reveals asymmetrical haploinsuffciency in tumor suppression. Genes Dev. 19, 1779-1786 (2005). (Pubitemid 41126917)
8. Di Cristofano, A., Pesce, B., Cordon-Cardo, C. & Pandolf, P.P. Pten is essential for embryonic development and tumour suppression. Nat. Genet. 19, 348-355 (1998). (Pubitemid 28357906)
9. Venkatachalam, S. et al. Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation. EMBO J. 17, 4657-4667 (1998). (Pubitemid 28377166)
10. Di Cristofano, A. & Pandolf, P. P. The multiple roles of PTEN in tumor suppression. Cell 100, 387-390 (2000).
11. Suzuki, A. et al. High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr. Biol. 8, 1169-1178 (1998). (Pubitemid 28494715)
12. Podsypanina, K. et al. Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc. Natl. Acad. Sci. USA 96, 1563-1568 (1999). (Pubitemid 29098491)
13. Morita, M. et al. HLF/HIF-2alpha is a key factor in retinopathy of prematurity in association with erythropoietin. EMBO J. 22, 1134-1146 (2003). (Pubitemid 36313597)
14. McDevitt, M.A., Shivdasani, R.A., Fujiwara, Y., Yang, H. & Orkin, S.H.A. "Knockdown" mutation created by cis-element gene targeting reveals the dependence of erythroid cell maturation on the level of transcription factor GATA-1. Proc. Natl. Acad. Sci. USA 94, 6781-6785 (1997). (Pubitemid 27281941)
15. +/- mice. Science 285, 2122-2125 (1999). (Pubitemid 29451429)
16. Hong, F. et al. RankProd: a bioconductor package for detecting differentially expressed genes in meta-analysis. Bioinformatics 22, 2825-2827 (2006). (Pubitemid 44742407)
17. Saal, L.H. et al. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res. 65, 2554-2559 (2005). (Pubitemid 40490050)
18. Bose, S. et al. Reduced expression of PTEN correlates with breast cancer progression. Hum. Pathol. 33, 405-409 (2002). (Pubitemid 34627590)
19. Richardson, A.L. et al. X-chromosomal abnormalities in basal-like human breast cancer. Cancer Cell 9, 121-132 (2006). (Pubitemid 43202662)
20. Carver, B.S. et al. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat. Genet. 41, 619-624 (2009).
21. Trotman, L.C. et al. Identifcation of a tumour suppressor network opposing nuclear Akt function. Nature 441, 523-527 (2006).